Navigation Links
Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
Date:5/7/2013

(PRWEB) May 07, 2013

Drug manufacturer Merck recently sought and earned U.S. Food and Drug Administration approval for a new drug that pairs its own cholesterol-lowering Zetia with a generic version of Lipitor, the blockbuster statin marketed by Pfizer before it lost patent protection in 2011. The Rottenstein Law Group, which represents clients in Lipitor lawsuits, is watching this development closely, noting that studies have established a link between Lipitor and Type 2 diabetes.

The new drug, Liptruzet, is found to lower cholesterol but does not lower the risk for cardiovascular disease, according to a May 3 New York Times article.* Despite Lipitor’s popularity** there is at least one study that shows it has its own share of risks. According to a study in the January 2012 edition of JAMA: Internal Medicine, there is a potential link between statins and a Type 2 diabetes risk in women.***

“The FDA makes regulatory choices every day, but this one is troubling,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “This is especially true when considering the side effects we hear about daily from clients, in addition to the impact these choices can have on Lipitor lawsuits.”

Prompted by the drug’s potentially serious side effects, plaintiffs across the nation are filing Lipitor lawsuits, many under consideration for consolidation into a multidistrict litigation (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (JPML)).

The Rottenstein Law Group operates the Lipitor Lawsuit Information Center. This page on the firm’s website includes a comprehensive look at Lipitor side effects and how to contact an attorney to determine if Lipitor patients are able to file a lawsuit.

*nytimes.com/2013/05/04/business/fda-approves-mercks-combination-drug-to-reduce-cholesterol.html?_r=0

**bloomberg.com/news/2013-04-30/pfizer-lowers-2013-forecast-after-sales-miss-analyst-estimates.html

***archinte.jamanetwork.com/article.aspx?articleid=1108676

About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and drugs. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
http://www.rotlaw.com

                            ###

Read the full story at http://www.prweb.com/releases/side-effects-lipitor/lipitor-recall/prweb10706791.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lipitor Diabetes Lawsuit Filed by South Carolina Woman Who Developed Type 2 Diabetes Allegedly Due to Lipitor Use, Alonso Krangle Investigating
2. New Lawsuit on Serious Birth Defects from Depakote: Now, AttorneyOne Can Provide Advice
3. Texas Woman Alleges Actos Caused her Bladder Cancer, Parker Waichman LLP Files Lawsuit on Victim’s Behalf
4. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
5. Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Protective Order in Federal C.R. Bard Vaginal Mesh Litigation, Bernstein Liebhard LLP Reports
6. Smith & Nephew Hip Recall News: Bernstein Liebhard LLP Notes Motion to Consolidate Smith & Nephew Lawsuits Filed in Tennessee State Courts
7. Stryker Hip Recall Lawsuits Stemming from Rejuvenate and ABG II Hip Stem Recall Continue to Mount in New Jersey Litigation
8. Imprelis Lawsuit Filed on Behalf of Indiana Country Club, Alleging That Imprelis Use Seriously Damaged the Club’s Landscape and Profits, Reports Wright & Schulte
9. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Actos Bladder Cancer Litigation
10. Pradaxa Lawsuits Move Forward, With Scheduling of Next Status Conference in Federal Pradaxa Litigation, Bernstein Liebhard LLP Reports
11. Alleged DePuy Knee Sleeve Failure Lawsuits Now Being Reviewed by Resource4thePeople Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... HOUSTON, Texas (PRWEB) , ... September 22, 2017 ... ... leading network of independent freestanding emergency rooms is celebrating the one year anniversary ... anniversary of our facility opening,” said Dr. Otinwa, Facility Medical Director of First ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... products at customers’ doorstep. According to Smart Mart, customers can now order vegetable, ... offer wearable, and customers can find clothing at discounted prices. Apart from this, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: